Removing Barriers to Clozapine: Clinical, Program, and Family Views
Removing Barriers to Clozapine: Clinical, Program, and Family Views
Information
Date & Time
-
-
Description
Clozapine remains the most effective treatment for treatment-resistant schizophrenia, yet it continues to be substantially underused. This interdisciplinary program examines the clinical, organizational, and family-level barriers that delay or prevent appropriate clozapine treatment. A psychiatrist, behavioral-health CEO, and family advocate will discuss patient selection, risk-benefit assessment, side-effect and laboratory monitoring, program infrastructure, family concerns, and practical strategies that can make clozapine treatment more accessible and sustainable. The discussion will emphasize evidence-based care while translating the evidence into real-world clinical and operational practice.
Educational Goal
Learning Objectives
Participants will be able to:
-
Identify at least three common clinical and systems-level barriers that contribute to underuse of clozapine in treatment-resistant schizophrenia.
-
Describe at least three evidence-based considerations for selecting, initiating, monitoring, and maintaining patients on clozapine.
-
Apply at least two practical strategies for reducing monitoring, adherence, and care-coordination barriers for patients and families receiving clozapine.
-
Explain how interdisciplinary collaboration among prescribers, treatment programs, patients, and families can improve continuity and long-term access to clozapine.
Target Audience
- Addiction Professional
- Counselor
- Marriage & Family Therapist
- Psychologist
- Social Worker
Presenters
Financially Sponsored By
- Lakewood Center